Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease

Summary. Moderate hyperhomocysteinaemia has been linked to an increased risk for cardiovascular diseases. Increased homocysteine concentrations may follow folate depletion due to insufficient dietary intake of the vitamin, but there is also some indication that immune activation could play a role. In this preliminary study, homocysteine, folate, and vitamin B12 concentrations were measured in 19 patients with Parkinson's disease, 61–90 years of age, and compared to a healthy control group of similar age and to neopterin concentrations as an indicator of immune activation. A subgroup of patients presented with increased homocysteine and low folate concentrations. Homocysteine levels correlated inversely with vitamins folate and B12 and positively with neopterin concentrations. Disturbed homocysteine metabolism in Parkinson's disease may be associated with vitamin deficiency and with immune system activation which may underlie folate depletion.

[1]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[2]  N. Dudman.  An alternative view of homocysteine , 1999, The Lancet.

[3]  D. Fuchs,et al.  N eopterin: Indicator of Oxidative Stress and Part of the Cytotoxic Armature of Activated Macrophages in Humans , 1998 .

[4]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[5]  Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. , 2000, Neurology.

[6]  D. Fuchs,et al.  Does disturbed homocysteine and folate metabolism in depression result from enhanced oxidative stress? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[7]  D. Fuchs,et al.  Increased Serum Neopterin Concentrations in Patients with Alzheimer’s Disease , 1999, Clinical chemistry and laboratory medicine.

[8]  T. Müller.  Non-dopaminergic drug treatment of Parkinson’s disease , 2001, Expert opinion on pharmacotherapy.

[9]  W. Kuhn,et al.  Nigral endothelial dysfunction, homocysteine, and Parkinson's disease , 1999, The Lancet.

[10]  N Turgan,et al.  Association between homocysteine and neopterin in healthy subjects measured by a simple HPLC-fluorometric method. , 2001, Clinical biochemistry.

[11]  D. Fuchs,et al.  Is Hyperhomocysteinemia due to the Oxidative Depletion of Folate rather than to Insufficient Dietary Intake? , 2001, Clinical chemistry and laboratory medicine.

[12]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[13]  K. Eriksson,et al.  Homocysteine Is Related to Neopterin and Endothelin-1 in Plasma of Subjects with Disturbed Glucose Metabolism and Reference Subjects , 2000, Angiology.

[14]  U. Hoffmann,et al.  Chlamydia pneumoniae seropositivity and hyperhomocysteinemia are linked in patients with atherosclerosis. , 2001, Clinical chemistry.

[15]  P. Mcgeer,et al.  The role of the immune system in neurodegenerative disorders , 1997, Movement disorders : official journal of the Movement Disorder Society.

[16]  B. Halliwell.  Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? , 1989, Acta neurologica Scandinavica. Supplementum.

[17]  I. Rosenberg,et al.  Serum Total Homocysteine Concentrations in the Third National Health and Nutrition Examination Survey (19911994): Population Reference Ranges and Contribution of Vitamin Status to High Serum Concentrations , 1999, Annals of Internal Medicine.

[18]  W. Kuhn,et al.  Hyperhomocysteinaemia in Parkinson’s disease , 1998, Journal of Neurology.

[19]  K. Mccully,et al.  Homocysteine metabolism and the oxidative modification of proteins and lipids. , 1993, Free radical biology & medicine.

[20]  D. Fuchs,et al.  Increased neopterin production and tryptophan degradation in advanced Parkinson's disease , 2002, Journal of Neural Transmission.

[21]  V. Lehmann,et al.  Modulation of tumor necrosis factor-alpha-mediated cytotoxicity by changes of the cellular methylation state: mechanism and in vivo relevance. , 1999, International immunology.

[22]  R Clarke,et al.  Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. , 1998, Archives of neurology.

[23]  R. Ness,et al.  Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. , 1998, American journal of obstetrics and gynecology.

[24]  D. Fuchs,et al.  Hyperhomocysteinemia in dementia , 2000, Neurobiology of Aging.

[25]  P. Ueland,et al.  Total homocysteine in plasma or serum: methods and clinical applications. , 1993, Clinical chemistry.

[26]  F. Leblhuber,et al.  Activated Immune System in Patients with Huntington's Disease , 1998, Clinical Chemistry and Laboratory Medicine.

[27]  D. Fuchs,et al.  The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. , 1992, Critical reviews in clinical laboratory sciences.